Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential R-CHOP, BEAM, Auto-SCT and Allo-SCT in MCL
NCT00946374Phase 2Unknown
- Sponsor
- Heidelberg University
- Start
- Jul 2004
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, pegylated liposomal doxorubicin, vincristine sulfate liposome injection, prednisone in mantle cell lymphoma (MCL), sponsored by Heidelberg University. Status: unknown.
02
Drugs
rituximabcyclophosphamidepegylated liposomal doxorubicinvincristine sulfate liposome injectionprednisone
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00946374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00946374.